Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecvayli | teclistamab | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Active | ||
Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
TBC | talquetamab | Relapsed or refractory multiple myeloma | Active | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Received | |||
Kymriah | tisagenlecleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete |